


Palonosetron hydrochloride

Cat. No.:	HY-A0021
CAS No.:	135729-62-3
Molecular Formula:	C ₁₉ H ₂₅ ClN ₂ O
Molecular Weight:	332.87
Target:	5-HT Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro

H₂O : 100 mg/mL (300.42 mM; Need ultrasonic)
DMSO : 3.33 mg/mL (10.00 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	3.0042 mL	15.0209 mL	30.0418 mL
	5 mM	0.6008 mL	3.0042 mL	6.0084 mL
	10 mM	0.3004 mL	1.5021 mL	3.0042 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: PBS
Solubility: 100 mg/mL (300.42 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 0.33 mg/mL (0.99 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 0.33 mg/mL (0.99 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 0.33 mg/mL (0.99 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Palonosetron hydrochloride is a 5-HT₃ antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). IC₅₀ Value: Target: 5-HT Receptor Palonosetron is the most effective of the 5-HT₃ antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy.

CUSTOMER VALIDATION

- PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Vishnu Murthy M, Srinivas K, Kumar R, Mukkanti K. Development and validation of a stability-indicating LC method for determining palonosetron hydrochloride, its related compounds and degradation products using naphthalethyl stationary phase. *J Pharm Biomed Anal.* 2011 Sep 10;56(2):429-35.
- [2]. Ajioka H, Morita F, Akizawa Y, Yoshida K, Kitamura R, Takimoto H. Pharmacological, pharmacokinetic, and clinical profile of palonosetron hydrochloride (ALOXI I.V. Injection 0.75 mg), a novel antiemetic 5-HT₃-receptor antagonist. *Nihon Yakurigaku Zasshi.* 2010 Aug;136(2):113-20.
- [3]. Ruhlmann C, Herrstedt J. Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting. *Expert Rev Anticancer Ther.* 2010 Feb;10(2):137-48.
- [4]. Trissel LA, Trusley C, Ben M, Kupiec TC. Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during simulated Y-site administration. *Am J Health Syst Pharm.* 2007 Jun 1;64(11):1209-13.
- [5]. Clark, Robin D.; Miller, Aaron B.; Berger, Jacob; Repke, David B.; Weinhardt, Klaus K.; Kowalczyk, Bruce A.; Eglon, Richard M.; Bonhaus, Douglas W.; Lee, Chi Ho; et al. 2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT₃ receptor antagonists. *J. Med. Chem.*, 1993, 36 (18), pp 2645-2657

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA